REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

19 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

05 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

24 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

13 Jun 2024 23:30:00 By Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the Jefferies Global Healthcare Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

21 May 2024 16:05:00 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

15 May 2024 16:05:00 By Nasdaq GlobeNewswire

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

24 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

23 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

14 Dec 2023 08:00:00 By Nasdaq GlobeNewswire